How Medical Device Reimbursement Works: Coding, Coverage, and Payment
2026-09-25 · Caduvo Team
FDA clearance only grants market access; reimbursement ensures providers get paid. Learn how coding, coverage, and payment work together and why planning starts before design freeze.
An FDA clearance gives you permission to sell a medical device in the United States. It does not mean anyone will pay for it. According to the NIH SEED Reimbursement Knowledge Guide for Medical Devices, the US medical device market represents approximately $156 billion—about 40 percent of the global market—with annual growth near 5 percent. Yet founders regularly discover that cleared products sit unused because hospital departments cannot bill for them, insurers classify them as experimental, or fee schedules fall short of direct production costs. Regulatory review answers whether a product is safe and effective; medical device reimbursement determines whether a sustainable business model exists.
The Three-Part Framework: Coding, Coverage, and Payment
Reimbursement operates across three distinct mechanisms: coding, coverage, and payment. If any one of the three breaks down, providers cannot collect revenue, and clinical adoption halts.
1. Coding: The Language of Billing
Codes identify the patient's condition, the setting of care, and the exact clinical service or technology delivered. Under the Health Insurance Portability and Accountability Act (HIPAA), electronic claims submitted to public and private payers must use standard national code sets, as outlined in the CMS Guide for Medical Technology Companies:
- Healthcare Common Procedure Coding System (HCPCS) Level I (CPT Codes): Maintained by the American Medical Association, Current Procedural Terminology describes physician services and outpatient procedures. Category I codes represent established clinical practices. Category III codes track emerging technologies and services, serving primarily as temporary tracking mechanisms without guaranteed payment.
- HCPCS Level II Codes: Maintained by the Centers for Medicare & Medicaid Services (CMS), these alphanumeric codes (a single letter followed by four numeric digits) identify products, supplies, and services not included in CPT. This includes durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS). MedTech teams evaluating their classification should review our guides on HCPCS vs CPT codes and what is an HCPCS code.
- International Classification of Diseases (ICD-10-CM and ICD-10-PCS): ICD-10 Clinical Modification (CM) reports patient diagnoses and conditions. ICD-10 Procedure Coding System (PCS) codes report inpatient surgical and medical procedures.
Securing a code does not mean a payer will cover the item. Coding simply provides the standardized data structure required to file an electronic claim.
2. Coverage: The Decision to Pay
Coverage defines whether an insurer will pay for a service or device for a specific patient population and clinical indication. Payers classify items into covered, non-covered, or investigational categories.
For Medicare, coverage requires meeting statutory definitions established by Congress. According to CMS coverage criteria, an item or service must meet three conditions:
- Fall within at least one statutory benefit category under Section 1861 of the Social Security Act (such as physician services, inpatient hospital care, or DMEPOS).
- Avoid specific statutory exclusions.
- Be determined "reasonable and necessary" for the diagnosis or treatment of illness or injury, or to improve the functioning of a malformed body member, under Section 1862(a)(1)(A) of the Act.
If a novel device falls outside every recognized benefit category in Section 1861, Medicare has no legal authority to pay for it, regardless of its clinical performance. For DMEPOS items, manufacturers can submit a standalone Benefit Category Determination (BCD) request directly to CMS (via DMEPOS@cms.hhs.gov) before or alongside an HCPCS code application.
3. Payment: The Dollar Amount Transferred
Payment establishes the specific reimbursement rate transferred to the healthcare provider or facility. Having an active code and a positive coverage policy guarantees nothing about rate adequacy.
CMS operates distinct fee-for-service payment systems across healthcare settings, as detailed in the agency's guidance for innovators. Rates under these systems are generally updated each year based on recent Medicare cost data or economic indices such as the Consumer Price Index for All Urban Consumers (CPI-U):
- Hospital Outpatient Prospective Payment System (OPPS): Pays hospitals for outpatient services. To support adoption of cost-intensive new technologies, CMS offers transitional pass-through payments for qualifying devices under OPPS, which provide temporary supplemental payment beyond the standard service rate.
- Medicare Physician Fee Schedule (PFS): Reimburses individual physicians and practitioners for outpatient professional services.
- Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS): Reimburses medical equipment and supplies for home use. Founders can assess how these rates operate through our review of the Medicare DME fee schedule.
- Bundled Payment Systems: Facility systems often package all supplies, devices, and operational overhead into a single payment for an entire episode of care. In bundled arrangements, the facility purchases your product directly from its fixed payment allocation. If a device adds substantial cost without reducing facility resource use or improving outcomes, the facility absorbs that financial deficit.
Facility evaluation groups examine these exact financial trade-offs before approving new inventory; review our breakdown of the hospital value analysis committee process to understand how hospitals audit these margins.
Medicare vs Commercial Payers: Distinct Rules
Medicare and private commercial health plans operate under completely different legal frameworks and evidentiary standards.
Medicare serves over 54 million beneficiaries through a formal administrative structure. Coverage determinations occur at two levels: national coverage determinations vs local coverage determinations. A National Coverage Determination (NCD) is issued directly by CMS, establishing uniform coverage across the country that binds all regional Medicare Administrative Contractors (MACs), administrative law judges, and appeals bodies. In the absence of an NCD, individual MACs establish Local Coverage Determinations (LCDs) under Section 1869(f)(2)(B) of the Act. Most Medicare coverage determinations are issued regionally at the MAC level.
Commercial health plans (such as UnitedHealthcare, Elevance, Aetna, and Cigna) develop proprietary medical policies independently. Commercial payers are not bound by MAC coverage policies or CMS benefit categories. Instead, private payers rely on health technology assessments (HTAs) that grade published clinical trial literature against current standard care.
This separation creates friction for teams transitioning from FDA clearance to commercial sales. When deciding between a 510(k) vs PMA, teams often rely on a 510(k) clearance predicated on proving substantial equivalence to a predicate device. While bench testing and mechanical equivalency can satisfy FDA clearance thresholds, commercial payers do not pay for equivalence. Payers require direct clinical proof of improved patient outcomes, reduced complication rates, or lower total cost of care. Without published clinical comparative data, private payers classify new 510(k)-cleared devices as experimental and investigational, blocking provider claims.
Why Reimbursement Strategy Starts Before Design Freeze
Postponing reimbursement planning until after regulatory clearance regularly introduces multi-year delays. According to NIH SEED device case studies, executing the clinical, regulatory, and reimbursement roadmap typically requires 1 to 3 years. If a company designs its clinical trials solely to demonstrate safety and effectiveness for FDA authorization, it may fail to collect the specific endpoints payers demand to support coverage.
To bridge this divide, the FDA Center for Devices and Radiological Health (CDRH) created the Early Payor Feedback Program. Run by the CDRH Payor Communication Task Force (contacted at CDRHPayorCommunications@fda.hhs.gov), this voluntary program allows device manufacturers to obtain structured input from commercial insurers and CMS regarding trial design and clinical evidence needs before finalizing their study protocols. The task force also oversees the Parallel Review program with CMS, which coordinates FDA marketing review and the Medicare NCD process simultaneously.
Early architectural decisions during device design also dictate coding and payment options. Deciding whether a physiological monitor functions as an integrated single-use system or a durable multi-year sensor with disposable components alters whether it requires DMEPOS categorization or an outpatient procedure code. These choices determine which statutory benefit categories apply.
Teams balancing regulatory workflows with a freedom to operate search and early medical device classification can use Caduvo to analyze existing HCPCS codes, evaluate active LCD coverage policies, and assess competitor coding pathways before locking hardware specifications.
Actionable Reimbursement Checklist for Device Founders
Use this operational sequence to establish a medical device reimbursement strategy during early development:
- Identify the exact care setting: Determine where the device will be used (hospital outpatient department, inpatient surgical suite, physician office, or patient home). This dictates which Medicare payment system applies, such as OPPS, the Physician Fee Schedule, or the DMEPOS fee schedule.
- Audit existing codes: Determine whether an established CPT Category I code or HCPCS Level II code accurately describes the device and procedure. If existing descriptors are inadequate, factor in the administrative timeline required to apply for a new code.
- Confirm the statutory benefit category: Cross-reference Section 1861 of the Social Security Act to verify that Medicare has statutory authority to cover the item. If the technology is an outpatient supply or device, evaluate whether a formal Benefit Category Determination request to CMS is necessary.
- Quantify facility impact: If the device will be used in a bundled payment environment, compare the device's target sale price against facility payment rates. Determine whether the device qualifies for supplemental payment paths, such as transitional pass-through payments under OPPS.
- Engage payers before trial protocols lock: Use initiatives like the CDRH Early Payor Feedback Program or consultations with a qualified medical device reimbursement consultant to review clinical study protocols. Align primary and secondary trial endpoints with the comparative effectiveness data that private health plans require for positive medical coverage determinations.
Sources
- https://seed.nih.gov/sites/default/files/2024-01/Reimbursement-Knowledge-Guide-for-Medical-Devices.pdf
- Medical Device Coverage Initiatives: Connecting with Payors via the Payor Communication Task Force | FDA
- CMS Guide for Medical Technology Companies and Other Interested Parties | CMS
- Medicare Coverage of Items and Services | CMS
General information, not regulatory, legal or reimbursement advice. Company and product names belong to their owners; a mention does not imply affiliation or endorsement. Report an error. Data and corrections policy.